title: Assessment and management of scleroderma lung disease.
abstract: Lung disease is a major cause of morbidity and is the leading cause of mortality in patients with systemic sclerosis, most commonly occurring as interstitial lung disease or as pulmonary hypertension. Cyclophosphamide has been used to treat the interstitial lung disease and a placebo-controlled trial is planned. Potent pulmonary vasodilators, many of which have been studied in primary pulmonary hypertension, are now undergoing study in patients with systemic sclerosis.
authors.affiliation: Medical University of South Carolina, Department of Medicine, Charleston 29425, USA.
authors.forename: M B
authors.initials: MB
authors.lastname: Bolster
authors.forename: R M
authors.initials: RM
authors.lastname: Silver
mesh_terms: D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D017563:Lung Diseases, Interstitial / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D012595:Scleroderma, Systemic / Q000150:complications* / Q000175:diagnosis